Celldex Therapeutics (CLDX) Posts Narrower than Expected Q2 Loss of 27c/Sh.

Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.95 million versus the consensus estimate of $2.43 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c